Immunome, Inc. announced the appointment of Kinney Horn as Chief Business Officer. Mr. Horn brings to Immunome extensive experience across life sciences corporate and business development, alliance management, and commercial strategy. Prior to joiningImmunome, Mr. Horn was Chief Business Officer of Olema Oncology.

In that role, he played an integral role in raising over $300M in capital, building the company, and expanding its pipeline through strategic transactions including the collaboration with Aurigene that produced the Company?s KAT6 program. Before Olema, he was an Entrepreneur in Residence at EcoR1 Capital. Mr. Horn spent 16 years at Genentech, identifying both preclinical and clinical stage business development opportunities, structuring strategic alliances, and negotiating deals.

During his time at Genentech, Mr. Hornclosed numerous transactions and managed contractual relationships representing over $30B in value. Prior to Roche?s acquisition of Genentech, Mr. Horn also worked with early-stage biotechnology companies that Genentech invested in through GenenFUND, Genentech?s private equityfund. He began his career in various investment banking and venture roles.

Mr. Horn has degrees in economics, international affairs and biochemistry from Mary Washington College and Georgetown University.